Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease

Bibliography

• ROSENDAAL FR: Thrombosis in the young: epidemiology and risk factors: a focus on venous thrombosis. Thromb. Haemost. (1997) 78(1):1-6.
   PubMed Web of Science ®Google Scholar
• NORDSTROM M, LINDBLAD B, BERGQVIST D et al.: A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J. Intern. Med. (1992) 232(2):155-160.
   PubMed Web of Science ®Google Scholar
• ANDERSON FA Jr, WHEELER HB, GOLDBERG RJ et al.: A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch. Intern. Med. (1991) 151(5):933-938.
   PubMed Web of Science ®Google Scholar
• AGNELLI G, CIMMINIELLO C, MENEGHETTI G et al.: Low ankle-brachial index predicts an adverse 1-year outcome after acute coronary and cerebrovascular events. J. Thromb. Haemost. (2006) 4(12):2599-2606.
   Google Scholar
• ROTHWELL PM, COULL AJ, SILVER LE et al.: Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet (2005) 366(9499):1773-1783.
   PubMed Web of Science ®Google Scholar
• CARO J, MIGLIACCIO-WALLE K, ISHAK KJ et al.: The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database. BMC Cardiovasc. Disord. (2005) 5:14.
   PubMedGoogle Scholar
• FUSTER V, BADIMON JJ, CHESEBRO JH: Atherothrombosis: mechanisms and clinical therapeutic approaches. Vasc. Med. (1998) 3(3):231-239.
   PubMedGoogle Scholar
• VORCHHEIMER DA, BECKER R: Platelets in atherothrombosis. Mayo Clin. Proc. (2006) 81(1):59-68.
   PubMed Web of Science ®Google Scholar
• BECKER RC, BOVILL EG, SEGHATCHIAN MJ et al.: Pathobiology of thrombin in acute coronary syndromes. Am. Heart J. (1998) 136(4 Part 2 Suppl.):S19-S31.
   PubMed Web of Science ®Google Scholar
• FERINGA HH, VAN WANING VH, BAX JJ et al.: Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J. Am. Coll. Cardiol. (2006) 47(6):1182-1187.
   PubMed Web of Science ®Google Scholar
• FLAKER GC, GRUBER M, CONNOLLY SJ et al.: Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am. Heart J. (2006) 152(5):967-973.
   PubMed Web of Science ®Google Scholar
• BRAUNWALD E, ANTMAN EM, BEASLEY JW et al.: ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J. Am. Coll. Cardiol. (2002) 40(7):1366-1374.
   PubMed Web of Science ®Google Scholar
• VAN DE WERF F, ARDISSINO D, BETRIU A et al.: Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur. Heart J. (2003) 24(1):28-66.
   PubMed Web of Science ®Google Scholar
• STONE GW, MCLAURIN BT, COX DA et al.: Bivalirudin for patients with acute coronary syndromes. N. Engl. J. Med. (2006) 355(21):2203-2216.
   PubMed Web of Science ®Google Scholar
• VENDROV AE, MADAMANCHI NR, HAKIM ZS et al.: Thrombin and NAD(P)H oxidase-mediated regulation of CD44 and BMP4-Id pathway in VSMC, restenosis, and atherosclerosis. Circ. Res. (2006) 98(10):1254-1263.
   PubMed Web of Science ®Google Scholar
• BEA F, KREUZER J, PREUSCH M et al.: Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. (2006) 26(12):2787-2792.
   PubMed Web of Science ®Google Scholar
• YUSUF S, ZHAO F, MEHTA SR et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. (2001) 345(7):494-502.
   PubMed Web of Science ®Google Scholar
• WAHLANDER K, ERIKSSON-LEPKOWSKA M, NYSTROM P et al.: Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model. Thromb. Haemost. (2006) 95(3):447-453.
   PubMed Web of Science ®Google Scholar
• ALBERS GW, DIENER HC, FRISON L et al.: Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA (2005) 293(6):690-698.
   PubMed Web of Science ®Google Scholar
• OLSSON SB: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet (2003) 362(9397):1691-1698.
   PubMed Web of Science ®Google Scholar
• CHRISTERSSON C, OLDGREN J, BYLOCK A et al.: Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction. J. Thromb. Haemost. (2005) 3(10):2245-2253.
   PubMed Web of Science ®Google Scholar
• WALLENTIN L, WILCOX RG, WEAVER WD et al.: Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet (2003) 362(9386):789-797.
   PubMed Web of Science ®Google Scholar
• HACKAM DG, EIKELBOOM JW: Antithrombotic therapy for peripheral arterial disease. Heart (2007) 93(3):303-308.
   PubMed Web of Science ®Google Scholar
• HACKAM DG, TAN MK, LIN PJ et al.: Supporting a call to action for peripheral artery disease: insights from two prospective clinical registries. J. Vasc. Surg. (2006) 44(4):776-781.
   PubMed Web of Science ®Google Scholar
• SCHULMAN S, LUNDSTROM T, WALANDER K et al.: Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study. Thromb. Haemost. (2005) 94(4):820-824.
   PubMed Web of Science ®Google Scholar
• HARENBERG J, JORG I, WEISS C: Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. Int. J. Toxicol. (2006) 25(3):165-169.
   PubMed Web of Science ®Google Scholar
• FIESSINGER JN, HUISMAN MV, DAVIDSON BL et al.: Ximelagatran versus low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA (2005) 293(6):681-689.
   PubMed Web of Science ®Google Scholar
• DOUKETIS JD, ARNEKLEV K, GOLDHABER SZ et al.: Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. Arch. Intern. Med. (2006) 166(8):853-859.
   PubMed Web of Science ®Google Scholar